Evidence map›Paper›PMID 42324555›Full record

ArticleWorld journal of surgical oncology2026

Targeting RELA and STAT3 regulates TNFRSF10A-mediated apoptosis in a novel apoptosis-based prognostic model for clear cell renal cell carcinoma.

Yuyou Deng, Changzhen Hao, Xiaobing Yang, Chengfan Yu, Ming Xia, Tian Wang

Abstract read
In one paragraph

Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuyou Deng *Department of Urology, Peking University International Hospital, No.1 Shengyuan Road, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China.
Changzhen Hao *Department of Urology, Peking University International Hospital, No.1 Shengyuan Road, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China.
Xiaobing YangDepartment of Urology, Peking University International Hospital, No.1 Shengyuan Road, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China.
Chengfan YuDepartment of Urology, Peking University International Hospital, No.1 Shengyuan Road, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China.
Ming XiaDepartment of Urology, Peking University International Hospital, No.1 Shengyuan Road, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China.
Tian WangDepartment of Urology, Peking University International Hospital, No.1 Shengyuan Road, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China. wangtian2026@126.com.

Funding

Peking University International Hospital In-Hospital Research Fund YN2024QX02
6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is the most common subtype of renal malignancy and remains a major cause of cancer-related mortality worldwide. Although advances in surgery, targeted therapy, and immunotherapy have improved outcomes for patients, reliable biomarkers for predicting prognosis remain limited. Therefore, robust gene-based prognostic models are urgently needed to improve risk stratification and guide individualized treatment strategies.

methodsWe developed a novel prognostic model integrating apoptosis and immune - related genes (AIRGs) to predict overall survival (OS) in patients with ccRCC.

resultUsing Gene Set Enrichment Analysis (GSEA) combined with least absolute shrinkage and selection operator (LASSO) Cox regression, we identified 7 key prognostic genes, namely, CCR4, TNFRSF10A, TEK, TGFA, CD14, IFITM1, and SEMA3G, that collectively demonstrated strong predictive performance in TCGA cohort with c-index = 0.711. Functional enrichment analyses revealed that apoptosis, immune regulation, and multiple oncogenic signaling pathways were significantly associated with the risk score, highlighting the critical role of the tumor microenvironment in ccRCC progression. Transcription factor binding analysis based on the JASPAR database suggested that RELA and STAT3 with scores of 0.829 and 0.951, respectively are potential upstream regulators within the prognostic network, particularly influencing TNFRSF10A expression. External validation using the International Cancer Genome Consortium (ICGC) dataset confirmed the robustness of the prognostic model with c-index = 0.612 Furthermore, in vitro experiments demonstrated that RELA and STAT3 regulate TNFRSF10A-mediated apoptotic signaling in ccRCC cells, providing mechanistic support for the bioinformatic findings.

conclusionThis study establishes a biologically informed and clinically relevant prognostic framework for ccRCC. Our findings highlight the therapeutic potential of targeting the RELA/STAT3-TNFRSF10A axis and contribute to the advancement of precision medicine in ccRCC.

Indexed as

ApoptosisBiomarkers, TumorCarcinoma, Renal CellKidney NeoplasmsReceptors, TNF-Related Apoptosis-Inducing LigandSTAT3 Transcription FactorTranscription Factor RelAGene Expression Regulation, NeoplasticHumansPrognosisSurvival RateTumor Cells, CulturedBiomarkers, TumorReceptors, TNF-Related Apoptosis-Inducing LigandRELA protein, humanSTAT3 protein, humanSTAT3 Transcription FactorTNFRSF10A protein, humanTranscription Factor RelAApoptosisDeath receptorPrognostic modelRenal cell carcinomaTranscription factor

Identifiers

PMID42324555
PMCPMC13536853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.